Latest News for: Study cgi

Edit

Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical ...

The Facts 20 Mar 2023
While the primary objective of the study was safety and tolerability of the drug, efficacy over baseline was also assessed ... Notably, of the 161 patients who were randomized, 153 (95%) completed the six-week treatment period and 144 (94% of the completers) entered the extension study (Study 015) ... About study 014/015.
Edit

Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

Pharmiweb 20 Mar 2023
Study results. Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia ... Detailed Study 014 results to be presented at the 36th ECNP Congress ... “The final results of study 014 are exciting for various reasons.
Edit

Call for Presentations and Posters Now Open for the CGI 2023 Integrated Care Conference

Longview News-Journal 17 Mar 2023
TEMPE, Ariz., March 17, 2023 /PRNewswire-PRWeb/ -- Cummings Graduate Institute for Behavioral Health Studies (CGI) is accepting ... About Cummings Graduate Institute for Behavioral Health Studies (CGI) ... SOURCE Cummings Graduate Institute for Behavioral Health Studies (CGI).
Edit

Newron to present at the 31st European Congress of Psychiatry

The Galveston Daily News 17 Mar 2023
The second poster will detail the characterization of “Responder” in TRS patients based on data from this study ... 6-month interim results from the first 100 patients in an ongoing international randomized study”; ... About study 014/015 ... Study 015 is the extension study to determine the long-term benefits of glutamate release inhibition.
Edit

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome ...

The Joplin Globe 11 Mar 2023
In the study, treatment with DAYBUE demonstrated statistically significant improvement compared to placebo on both co-primary efficacy endpoints, as measured by the change from baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) total score (p=0.018) and the Clinical Global Impression-Improvement (CGI-I) scale score (p=0.003) at week 12.
Edit

Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% ...

Eagle-Tribune 09 Mar 2023
Clinician Global Impression of Change (CGI-C)2.42<0.0001 ... • CGI-S Height-1.67<0.0001. • CGI-S Leaking-0.920.0047 ... All twelve participants in the study demonstrated improvements on the PGI-C and CGI-C scales with all rated as either “Much Improved” or “Very Much Improved” by the clinicians after twelve weeks of treatment with QTORIN™ rapamycin.
Edit

Praxis Precision Medicines Announces Topline Results from the Essential1 Study of ...

Eagle-Tribune 03 Mar 2023
Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23 ... Ulixacaltamide was well tolerated in the Essential1 study, with no new safety findings.
Edit

Cummings Graduate Institute's Integrated Care Conference Returns October 9-11, 2023

Victoria Advocate 20 Feb 2023
20, 2023 /PRNewswire-PRWeb/ -- Cummings Graduate Institute for Behavioral Health Studies (CGI) is immensely proud to host the 2023 Integrated Care Conference taking place October 9-11, 2023, at the Gila River Resorts – Wild Horse Pass & Conference Center in Chandler, Arizona.
Edit

Nfinite and Coresight Research Find Retailers Increasingly Investing in CGI and AI for Visually Engaging ...

Victoria Advocate 16 Feb 2023
The research uncovers that retailers are bolstering e-commerce shopping capabilities with CGI and AI to deliver more personalized and visually engaging online shopping experiences ... The study also found that AI, an emerging topic in product visual creation, can multiply the benefits of CGI through automation.
Edit

Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide ...

The Galveston Daily News 16 Feb 2023
Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously ... In addition, the mean change for the severity of illness (as measured by Clinical Global Impression of Severity (CGI-S)) showed a statistically significant improvement at one year compared to baseline ... About study 014/015.
Edit

Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Pharmiweb 16 Feb 2023
Study results/Study ... Initiation of a pivotal, international, randomized, placebo-controlled study&nbsp;in TRS patients expected in 2023 ... Results from these same 100 patients at six weeks and six months in study 014/015 have been reported previously ... The enrollment of patients in study 014 has been completed, with 161 subjects randomized.
Edit

Genesis: Paradise Lost

The Epoch Times 09 Jan 2023
... research, this film explores the context of the highly studied and hotly-debated book of Genesis.
Edit

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on ...

The Galveston Daily News 03 Jan 2023
The results follow on from the Company’s announcement on June 7, 2022, summarizing the data from an interim analysis of the first 100 patients to have finished six weeks of treatment in this study ... These results from studies 014/015 make us excited about the clinical potential of evenamide ... About study 014/015.
Edit

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Pharmiweb 03 Jan 2023
Study results ... &nbsp;Newron plans to commence a pivotal study in treatment-resistant schizophrenia in 2023 ... The results follow on from the Company’s announcement on June 7, 2022, summarizing the data from an interim analysis of the first 100 patients to have finished six weeks of treatment in this study ... About study 014/015.
Edit

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

Eagle-Tribune 10 Nov 2022
IGALMI was not studied for longer than 24 hours after the first dose ... The studies will assess agitation as measured by the changes from baseline in the Positive and Negative Syndrome Scale-Excitatory Component (PEC) total score, and include Pittsburgh Agitation Scale (PAS) scores and Clinical Global Impression (CGI).

Most Viewed

×